Sign up for free insights newsletter
Celltrion Inc

Celltrion Inc

068270KO

Need professional-grade analysis? Visit stockanalysis.com

₩199,600.00
-1.19%
End of day
Market Cap

$46.93T

P/E Ratio

111.02

Employees

2,680

Dividend Yield

0.36%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.471.450.760.580.52
Calmar-4.352.521.040.680.46
Sharpe-1.300.960.500.380.30
Omega0.461.241.151.121.06
Martin-6.516.463.131.641.93
Ulcer13.758.026.838.558.69

Celltrion Inc (068270) Price Performance

Celltrion Inc (068270) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW199600.00, down 1.19% from the previous close.

Over the past year, 068270 has traded between a low of KRW145353.36 and a high of KRW248500.00. The stock has gained 12.4% over this period. It is currently 19.7% below its 52-week high.

Celltrion Inc has a market capitalization of $46.93T, with a price-to-earnings ratio of 111.02 and a dividend yield of 0.36%.

About Celltrion Inc

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.

Company Info

Exchange
KO
Currency
KRW

Financial Metrics

Revenue (TTM)
$3.90T
EBITDA
$1.19T
Profit Margin
18.94%
EPS (TTM)
N/A
Book Value
17439141.58

Technical Indicators

52 Week High
₩251,000.00
52 Week Low
₩144,012.83
50 Day MA
₩196,454.00
200 Day MA
₩176,040.40
Beta
0.20

Valuation

Trailing P/E
111.02
Forward P/E
35.21
Price/Sales
11.40
Price/Book
2.70
Enterprise Value
$47.01T